Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

NCT05051436 is registered in ClinicalTrials.gov with Philip Kern as lead sponsor.

NCT NCT05051436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05051436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
Lead sponsor
Philip Kern
Phase
Phase 4
Overall status
Recruiting
Start date
December 13, 2021
Completion date
January 31, 2027
Enrollment
96 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, pre-diabetes